Typology of drug discontinuation trials - Methodological recommendations

Abstract

Objective: Due to the increasing concerns about polypharmacy, there is a growing need for clinical recommendations for drug discontinuation. This requires studies investigating the process on several levels. This paper addresses the methodological problems of drug discontinuation trials (DDTs). To that end, we offer a new typology of research aims and corresponding methodological recommendations for trials evaluating drug discontinuation.Study Design and Setting: Multi-stage development process, including literature search and expert panels.Results: Clinical trials are only required in cases of scientific uncertainty. We identified three situations of uncertainty associated with drug discontinuation from which we derived three study types: 1) Uncertainty regarding the effectiveness and/or safety of a drug; 2) Uncertainty regarding the procedure of discontinuing a previously taken drug; 3) Uncertainty regarding the effectiveness of complex strategies used to discontinue one or more drugs. We developed specific methodological recommendations for each study type. Conclusion:We offer a comprehensive definition of research aims, study designs, and methodological recommendations regarding DDTs. The typology we propose can help investigators clarify their research aims and study design. The type-specific methodological recommendation should improve the quality of future drug discontinuation trials.

Mapping the methodological diversity of published drug discontinuation studies—a scoping review of study topics, objectives, and designs

“…They identified three situations in which there is often uncertainty when discontinuing medication. They defined three types of studies: (1) uncertainty regarding the effectiveness and/or safety of a drug, (2) uncertainty regarding the procedure of discontinuing a previously taken drug, and (3) uncertainty regarding the effectiveness of complex strategies used to discontinue one or more drugs [ 22 ]. In order to optimally design and adequately report DDTs planned for the future, the CONSORT Statement was elaborated by Blom et al [ 23 ].…”